Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NTLA
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics (NTLA) alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
March 21, 2025 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics stock may face continued pressure due to class action lawsuit alleging securities fraud and company's decision to halt NTLA-3001 research.
The lawsuit and research discontinuation suggest potential financial and reputational damage for Intellia Therapeutics, which could negatively impact investor sentiment and stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100